RAPT

RAPT Therapeutics, Inc. RAPT

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Net income

$-17.58M

Quarter to Sep 30

Free cash flow

$-12.46M

Quarter to Sep 30

Top Institutional Holders

as of Q4 2025
$1.04B total
Medicxi Ventures Management (Jersey) Ltd
$94.63M0.0%
TCG Crossover Management, LLC
$87.47M+57.8%
FCPM III SERVICES B.V.
$62.09M+432.6%
ORBIMED ADVISORS LLC
$55.64M+51.2%
RTW INVESTMENTS, LP
$55.45M+11.3%
Foresite Capital Management VI LLC
$52.92M0.0%
Siren, L.L.C.
$46.57M+136.9%
VANGUARD GROUP INC
$40.20M+70.5%
ADAR1 Capital Management, LLC
$34.53M+100.8%
Frazier Life Sciences Management, L.P.
$33.31MNew
BRAIDWELL LP
$31.49MNew
Redmile Group, LLC
$30.01M+60.3%
PERCEPTIVE ADVISORS LLC
$27.97M+349.1%
Soleus Capital Management, L.P.
$25.88M+42.0%
Nantahala Capital Management, LLC
$25.54M+21.0%
Ikarian Capital, LLC
$22.53M+8.2%
Caligan Partners LP
$21.83MNew
STATE STREET CORP
$21.67M+1611.5%
CITADEL ADVISORS LLC
$20.04M+3710.7%
GREAT POINT PARTNERS LLC
$19.68MNew
Octagon Capital Advisors LP
$19.44MNew
BlackRock, Inc.
$16.47M+443.2%
BOONE CAPITAL MANAGEMENT LLC
$15.93M-39.9%
SUSQUEHANNA INTERNATIONAL GROUP, LLP
$14.39M+836.2%
MPM BioImpact LLC
$13.48MNew
See all 106 institutional holders →
Reading the latest SEC filing…

Key Metrics

Net Income

Q3 2025
EDGAR

EPS (Diluted)

Q3 2025
EDGAR

ROIC

Q3 2025
EDGAR

Free Cash Flow

Q3 2025
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/RAPT

Earnings Per Share

13fpro.ai/company/RAPT

Loading ratio trend…

RAPT key financials by period

Reported revenue, net income and operating margin by fiscal year, from RAPT Therapeutics, Inc.'s annual filings on SEC EDGAR.

RAPT Therapeutics, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2022$1.5M$-83.8M—
FY 2021$3.8M$-69.2M—
FY 2020$5.0M$-52.9M—
Source: RAPT filings on SEC EDGAR →

RAPT insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About RAPT Therapeutics, Inc. (RAPT): stock profile, AI score and financials

RAPT Therapeutics, Inc. (RAPT) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. RAPT is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q3 2025), RAPT Therapeutics, Inc. reports net income of $-17.6M, free cash flow of $-12.5M. Top institutional holders of RAPT by reported 13-F value include Medicxi Ventures Management (Jersey) Ltd, TCG Crossover Management, FCPM III SERVICES B.V., based on the most recent SEC filings. RAPT trades on the Nasdaq exchange and files with the SEC under CIK 1673772. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate RAPT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for RAPT Therapeutics, Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1673772 →